4 Results

People

  1. Zhang
    Zhang
  2. Zelefsky
    Zelefsky
  3. Cohen
    Cohen
  4. Flynn
    Flynn
  5. Kollmeier
    Kollmeier
  6. McBride
    McBride
  7. Yamada
    Yamada
  8. Beaudry
    Beaudry
  9. Berger
    Berger
  10. Brennan
    Brennan

Groups

  1. Biostatistics Service (4)
  2. Epidemiology and Biostatistics (4)
  3. Radiation Oncology, Department of (4)
  4. Survivorship Research (4)
  5. GDMT, Radiation Oncology (2)
  6. Gynecology Disease Management Team (2)
  7. Medical Physics (2)
  8. Radiotherapy Physics Service (2)
  9. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  10. Breast Medicine Service (1)
  1. "follow up"
  2. "Elsevier Science, Inc."
  3. "Zhigang Zhang"
Formats
  1. Journal Article (4)
Groups
  1. Biostatistics Service (4)
  2. Epidemiology and Biostatistics (4)
  3. Radiation Oncology, Department of (4)
  4. Survivorship Research (4)
  5. GDMT, Radiation Oncology (2)
  6. Gynecology Disease Management Team (2)

More Groups

People
  1. Zhigang Zhang (4)
  2. Michael Zelefsky (3)
  3. Gilad Cohen (2)
  4. Jessica Flynn (2)
  5. Marisa Kollmeier (2)
  6. Sean McBride (2)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2015 (1)
  4. 2010 (1)
Publications
  1. Brachytherapy (2)
  2. Journal of Urology (1)
  3. Lancet (1)
Publishers
  1. Elsevier Science, Inc. (4)

Results (4)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost
    Journal Article

    Kollmeier, M. A.; Gorovets, D.; Flynn, J.; McBride, S.; Brennan, V.; Beaudry, J.; Cohen, G.; Damato, A.; Zhang, Z.; Zelefsky, M. J.
    Brachytherapy (2022)

    Fulltext@MSK | Save
  • Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer
    Journal Article

    Zumsteg, Z. S.; Spratt, D. E.; Romesser, P. B.; Pei, X.; Zhang, Z.; Kollmeier, M.; McBride, S.; Yamada, Y.; Zelefsky, M. J.
    Journal of Urology (2015)

    Fulltext@MSK | Save
  • Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT
    Journal Article

    Deutsch, I.; Zelefsky, M. J.; Zhang, Z.; Mo, Q.; Zaider, M.; Cohen, G.; Cahlon, O.; Yamada, Y.
    Brachytherapy (2010)

    Fulltext@MSK | Save